ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AVEO AVEO Pharmaceuticals Inc

15.00
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
AVEO Pharmaceuticals Inc NASDAQ:AVEO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.00 14.99 15.00 0 01:00:00

Aveo Oncology Gets Fast Track Designation for Carcinoma Treatment

20/09/2021 12:44pm

Dow Jones News


AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more AVEO Pharmaceuticals Charts.

By Chris Wack

 

Aveo Oncology said the Food and Drug Administration has granted fast track designation to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma.

The biopharmaceutical company said ficlatuzumab is its investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor.

In June, the company reported positive results from a randomized confirmatory Phase 2 study of ficlatuzumab, alone or in combination with cetuximab, an EGFR-targeted antibody, in patients with metastatic head and neck squamous cell carcinoma who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab.

Aveo said a shortage of required key raw materials and manufacturing supplies also used in Covid-19 vaccine manufacturing has delayed the delivery of the clinical supply of ficlatuzumab. The company sees the potential start date for a registrational study in HPV negative head and neck squamous cell carcinoma in 2023, and expects to continue to discuss potential ficlatuzumab pivotal study designs with the FDA and to continue ongoing partnership dialogues.

Aveo Oncology shares were up 16% to $8 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

September 20, 2021 07:29 ET (11:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year AVEO Pharmaceuticals Chart

1 Year AVEO Pharmaceuticals Chart

1 Month AVEO Pharmaceuticals Chart

1 Month AVEO Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock